1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

30 May 2024
Admin
News Article

Novartis Canada, Clarius Partner for Psoriatic Arthritis Care in Canada

Overview

Novartis Pharmaceuticals Canada Inc. announced a partnership with Clarius Mobile Health (Clarius) as part of a dedicated effort to aid in early detection of psoriatic arthritis in Canada. By improving access to ultrasound technology, rheumatologists will be able to identify diagnostic markers sooner, and may positively impact the timeline to diagnosis for PsA patients.

Words from President: Novartis Canada

“At Novartis, we recognize the tremendous potential AI holds for our industry and the healthcare landscape at large,” said Mark Vineis, country president at Novartis Canada.
“The partnership with Clarius has the potential to transform PsA detection, with the possibility of scaling to other Immunology indications, across specialties and beyond Canada.”

Works for Improving Accessibility to Medical Imaging

Novartis and Clarius share a commitment to improving accessibility to medical imaging in Canada.
This agreement will facilitate access to handheld ultrasound devices for rheumatologists and deliver a robust training, support and education journey through in-person, virtual and asynchronous events.
As a result of the partnership, Novartis will generate evidence to measure and monitor adoption, usage and impact, and determine how usage of ultrasound in routine practice is related to early detection of PsA.

From Vancouver General Hospital

“The use of point-of-care ultrasound empowers us as rheumatologists to aid in patient education and adherence, as well as therapeutic confidence, to significantly enhance patient care,” said Dr. Mohammad Bardi, clinical instructor at the University of British Columbia and Staff Rheumatologist, Vancouver General Hospital.
“The Clarius handheld ultrasound enables us to provide the best care possible, especially in settings where access to the sizeable cart-based ultrasound systems is not readily available.”

Clarius

Clarius is a pioneer in the medical device field, miniaturizing ultrasound technology to improve medical imaging accessibility.
Approved by Health Canada in 2022, the third generation Clarius HD3 boasts a product line of high-performance handheld ultrasound scanners that wirelessly connect to clinician Apple and Android smart devices with an AI-powered application.
The Clarius app uses advanced artificial intelligence technology to automatically display an optimized image in real-time, enabling clinicians to make informed decisions at the point of care rather than referring patients to an imaging centre.

Words from CEO: Clarius

“We are inspired by Novartis’ mission to improve care for PsA patients and their novel approach to help accelerate diagnosis with real-time ultrasound imaging,” said Ohad Arazi, president and CEO at Clarius.
“We believe that this type of partnership between a pharmaceutical and a medical technology company can play a tremendous role in improving patient outcomes and reducing the burden on our healthcare system.

Novartis

Novartis is a focused innovative medicines company.
Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease.

Clarius

Clarius is on a mission to make accurate, easy-to-use, and affordable ultrasound tools available to all medical professionals in every specialty.
With decades of experience in medical imaging, the team knows that great ultrasound imaging improves confidence and patient care.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!